within Pharmacolibrary.Drugs.ATC.J;

model J05AD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 7.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,
    adminCount     = 1,
    Vd             = 0.00032,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Foscarnet is an antiviral drug that acts as a pyrophosphate analog, inhibiting viral DNA polymerases and reverse transcriptases. It is mainly used for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS and for acyclovir-resistant herpes simplex virus (HSV) infections. Foscarnet is approved for medical use in the United States and other countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult HIV-positive patients with normal renal function after intravenous infusion.</p><h4>References</h4><ol><li><p>Aweeka, F, et al., &amp; Jacobson, MA (1989). Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. <i>Antimicrobial agents and chemotherapy</i> 33(5) 742–745. DOI:<a href=&quot;https://doi.org/10.1128/AAC.33.5.742&quot;>10.1128/AAC.33.5.742</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2546491/&quot;>https://pubmed.ncbi.nlm.nih.gov/2546491</a></p></li><li><p>Sjövall, J, et al., &amp; Saarimäki, M (1988). Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. <i>Clinical pharmacology and therapeutics</i> 44(1) 65–73. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1988.114&quot;>10.1038/clpt.1988.114</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2968875/&quot;>https://pubmed.ncbi.nlm.nih.gov/2968875</a></p></li><li><p>Minor, JR, &amp; Baltz, JK (1991). Foscarnet sodium. <i>DICP : the annals of pharmacotherapy</i> 25(1) 41–47. DOI:<a href=&quot;https://doi.org/10.1177/106002809102500109&quot;>10.1177/106002809102500109</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1848959/&quot;>https://pubmed.ncbi.nlm.nih.gov/1848959</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AD01;
